Table II.

Univariate and multivariate analyses of recurrence-free interval and overall survival.

	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	P-value	HR (95% CI)	P-value
Recurrence-free interval
Age (years)
High	1.02 (0.984–1.05)	0.327
pT stage
pT2,3,4	2.04 (0.910–4.57)	0.084
Nodal status
Positive	9.10 (3.88–21.3)	0.007	8.92 (3.79–21.0)	<0.001
Nuclear grade
III	1.91 (0.640–5.67)	0.247
Lymphovascular invasion
Positive	5.17 (0.697–38.4)	0.108
Progesterone receptor status
Negative	0.827 (0.367–1.86)	0.646
Ki67 labeling index
High	1.03 (1.02–1.05)	0.003	1.03 (1.01–1.06)	0.004
p53 status
Positive	1.32 (0.576–3.02)	0.512
Chemotherapy
Yes	1.51 (0.647–3.54)	0.339
Overall survival
Age (years)
High	1.05 (0.985–1.11)	0.140
pT stage
pT2,3,4	6.45 (1.29–32.3)	0.023	1.52 (0.257–9.03)	0.643
Nodal status
Positive	40.0 (7.94–201.0)	<0.001	29.5 (4.91–177.0)	<0.001
Nuclear grade
III	4.05 (0.740–22.2)	0.107
Lymphovascular invasion
Positive	27.2 (0.009–84.3)	0.420
Progesterone receptor status
Negative	0.697 (0.170–2.86)	0.616
Ki67 labeling index
High	1.04 (1.01–1.08)	0.021	1.04 (0.996–1.09)	0.074
p53 status
Positive	2.02 (0.503–8.11)	0.321
Chemotherapy
Yes	3.14 (0.784–12.6)	0.106

HR, hazard ratio; CI, confidence interval.